VIDEO: Studies shed further light on guselkumab’s use for psoriasis

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the interleukin-23 inhibitor guselkumab from the Maui Derm 2024 meeting.

Chovatiya, assistant professor of dermatology at Northwestern University Feinberg School of Medicine, reviewed results of the VISIBLE study, which examined guselkumab (Tremfya, Janssen) in treating patients with skin of color, and also looked at quality-of-life studies into the drug’s use in psoriasis treatment.

“What was seen is that there was a really high degree of achieving endpoints in both of these studies, giving us more confidence now to talk to our many different patients about what they might uniquely expect when we think about therapy with this particular medication,” Chovatiya said.